S&P 500   4,293.49 (+0.26%)
DOW   33,673.79 (-0.26%)
QQQ   357.33 (+0.76%)
AAPL   184.45 (+1.93%)
MSFT   338.25 (+0.85%)
META   274.12 (+0.55%)
GOOGL   126.99 (+1.86%)
AMZN   125.19 (+0.76%)
TSLA   219.14 (+2.42%)
NVDA   391.95 (-0.34%)
NIO   7.79 (+3.04%)
BABA   84.02 (-0.30%)
AMD   118.73 (+0.74%)
T   15.34 (+0.85%)
F   12.67 (+2.26%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.57%)
GE   104.83 (-0.92%)
DIS   90.37 (-0.44%)
AMC   4.62 (+1.54%)
PFE   38.79 (+1.12%)
PYPL   64.94 (+1.53%)
NFLX   412.96 (+3.12%)
S&P 500   4,293.49 (+0.26%)
DOW   33,673.79 (-0.26%)
QQQ   357.33 (+0.76%)
AAPL   184.45 (+1.93%)
MSFT   338.25 (+0.85%)
META   274.12 (+0.55%)
GOOGL   126.99 (+1.86%)
AMZN   125.19 (+0.76%)
TSLA   219.14 (+2.42%)
NVDA   391.95 (-0.34%)
NIO   7.79 (+3.04%)
BABA   84.02 (-0.30%)
AMD   118.73 (+0.74%)
T   15.34 (+0.85%)
F   12.67 (+2.26%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.57%)
GE   104.83 (-0.92%)
DIS   90.37 (-0.44%)
AMC   4.62 (+1.54%)
PFE   38.79 (+1.12%)
PYPL   64.94 (+1.53%)
NFLX   412.96 (+3.12%)
S&P 500   4,293.49 (+0.26%)
DOW   33,673.79 (-0.26%)
QQQ   357.33 (+0.76%)
AAPL   184.45 (+1.93%)
MSFT   338.25 (+0.85%)
META   274.12 (+0.55%)
GOOGL   126.99 (+1.86%)
AMZN   125.19 (+0.76%)
TSLA   219.14 (+2.42%)
NVDA   391.95 (-0.34%)
NIO   7.79 (+3.04%)
BABA   84.02 (-0.30%)
AMD   118.73 (+0.74%)
T   15.34 (+0.85%)
F   12.67 (+2.26%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.57%)
GE   104.83 (-0.92%)
DIS   90.37 (-0.44%)
AMC   4.62 (+1.54%)
PFE   38.79 (+1.12%)
PYPL   64.94 (+1.53%)
NFLX   412.96 (+3.12%)
S&P 500   4,293.49 (+0.26%)
DOW   33,673.79 (-0.26%)
QQQ   357.33 (+0.76%)
AAPL   184.45 (+1.93%)
MSFT   338.25 (+0.85%)
META   274.12 (+0.55%)
GOOGL   126.99 (+1.86%)
AMZN   125.19 (+0.76%)
TSLA   219.14 (+2.42%)
NVDA   391.95 (-0.34%)
NIO   7.79 (+3.04%)
BABA   84.02 (-0.30%)
AMD   118.73 (+0.74%)
T   15.34 (+0.85%)
F   12.67 (+2.26%)
MU   68.14 (-1.49%)
CGC   0.79 (-4.57%)
GE   104.83 (-0.92%)
DIS   90.37 (-0.44%)
AMC   4.62 (+1.54%)
PFE   38.79 (+1.12%)
PYPL   64.94 (+1.53%)
NFLX   412.96 (+3.12%)
NASDAQ:IMTX

Immatics (IMTX) Price Target & Analyst Ratings

$10.15
-0.03 (-0.29%)
(As of 12:58 PM ET)
Compare
Today's Range
$9.95
$10.34
50-Day Range
$5.92
$10.18
52-Week Range
$5.90
$13.60
Volume
127,618 shs
Average Volume
331,014 shs
Market Capitalization
$778.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

Immatics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$17.67
74.06% Upside
High Prediction$25.00
Average Prediction$17.67
Low Prediction$12.00
TypeCurrent
6/5/22 to 6/5/23
1 Month Ago
5/6/22 to 5/6/23
3 Months Ago
3/7/22 to 3/7/23
1 Year Ago
6/5/21 to 6/5/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.67$19.75$27.00$26.00
Predicted Upside74.06% Upside172.79% Upside169.60% Upside223.38% Upside
Get Immatics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.


IMTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IMTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Immatics Stock vs. The Competition

TypeImmaticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside73.54% Upside473.73% Upside28.69% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/30/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$12.00+67.13%
3/24/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$16.00+137.39%
3/23/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$28.00 ➝ $25.00+257.14%
(Data available from 6/5/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












IMTX Price Target - Frequently Asked Questions

What is Immatics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Immatics stock is Buy based on the current 3 buy ratings for IMTX. The average twelve-month price prediction for Immatics is $17.67 with a high price target of $25.00 and a low price target of $12.00. Learn more on IMTX's analyst rating history.

Do Wall Street analysts like Immatics more than its competitors?

Analysts like Immatics more than other Medical companies. The consensus rating score for Immatics is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how IMTX compares to other companies.

Does Immatics's stock price have much upside?

According to analysts, Immatics's stock has a predicted upside of 153.35% based on their 12-month price targets.

What analysts cover Immatics?

Immatics has been rated by Bryan, Garnier & Co, Chardan Capital, and Mizuho in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:IMTX) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -